AAN 2024: Troriluzole may be taken with food, data suggest
Troriluzole, a new formulation of the approved amyotrophic lateral sclerosis (ALS) treatment riluzole, can be taken with or without…
Articles by Marisa Wexler, MS
AAN 2024: Stem cell therapy for ALS slows disease in some patients
Stem cell therapy, specifically treatment with mesenchymal stem cells or MSCs, did not substantially alter disease progression among people with…
Blocking KCNJ2 protein may reduce risk of ALS after brain injury: Study
In people who experience a traumatic brain injury, or TBI — which is linked to a greater likelihood of developing…
Taking part in certain recreational activities may increase risk of ALS
Taking part in certain recreational activities, including gardening, golfing, woodworking, and hunting, may increase the risk of developing amyotrophic…
MDA 2024: Blocking protein shows promise for genetic form of ALS
Blocking a protein called PTP sigma led to better nerve survival and motor function in a mouse model of…
ALS treatment Relyvrio fails trial, may be withdrawn from market
Relyvrio (sodium phenylbutyrate and taurursodiol), an approved treatment for people with amyotrophic lateral sclerosis (ALS), has failed to…
MDA 2024: Blood biomarkers may help predict ALS progression rates
New data show that blood-based measures, including levels of markers of nerve damage and chemical DNA modifications, can help predict…
MDA 2024: Planned Phase 3b trial aims to support NurOwn’s approval
Note: This story was updated March 6, 2024, to correct the poster was presented by Brainstorm’s executive vice president…
MDA 2024: Most patients don’t get recommended treatments for ALS
While the most recent guidelines for treating amyotrophic lateral sclerosis (ALS) recommend that patients receive three available treatments together,…
Health Canada rejects masitinib application; reconsideration sought
Health Canada has issued a notice of noncompliance-withdrawal saying it won’t approve the oral therapy masitinib as an add-on…